Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tay Therapeutics Limited is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, RAO, PADMAJA S, and is located within 1 distinct art unit. This represents a very focused prosecution profile, where all active engagement with the USPTO is channeled through a single point of contact. The concentration in 1 distinct art unit suggests that the technology being patented falls into a specific niche within the broader Biotechnology & Pharmaceuticals field.
RAO, PADMAJA S is the busiest examiner for this portfolio, currently managing 1 pending office action. Because there is only 1 pending office action in the entire portfolio, this examiner's role is central to the company's immediate patent goals. For practitioners, this means that the strategy is entirely dependent on the feedback from RAO, PADMAJA S. There are no other pending actions or examiners to provide a comparative baseline for prosecution within this technology area. Success for Tay Therapeutics Limited in this instance relies on successfully addressing the specific concerns raised in the 1 pending office action within its designated art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575006 | PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575006 | PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | RAO, PADMAJA S | 1627 | §102DP | Non-Final OA | — | Pending | Dec 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial